STEVEN A YOUNG:CONV001654 [13-005393]

代表16个NIH研究所和中心的NIH神经科学研究蓝图宣布了神经治疗学的巨大挑战，以解决神经系统疾病有效药物的缺乏。为了迎接这一重大挑战，NIH蓝图正在开创一种新的药物开发模式-一种将行业药物开发专业知识与创新疾病生物学相结合的网络，这是NIH资助研究的优势。蓝图神经治疗网络将作为一个“虚拟制药”（http：//neuroscienceblueprint.nih.gov/bpdrugs/index.htm）运行。具有令人信服的治疗原理和药物开发项目起始材料的神经科学研究人员（主要研究者）将与设计和指导药物开发计划的高级，行业经验丰富的顾问相匹配。主要研究者将进行生物活性测定和生物学工作，由NIH通过单独合同确定和资助的合同研究组织（CRO）将实施所有其他药物开发活动。参与项目的主要研究者、顾问、NIH工作人员和CRO工作人员将组成牵头开发团队（LDT）。

the NIH Blueprint for Neuroscience Research, representing sixteen NIH Institutes and Centers, announced a Grand Challenge for Neurotherapeutics to address the paucity of effective drugs for disorders of the nervous system. To meet this Grand Challenge, the NIH Blueprint is pioneering a new model for drug development�a network that integrates industry drug development expertise with the innovative disease biology that is the strength of NIH-funded research. The Blueprint Neurotherapeutics Network will operate as a �virtual pharma� (http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm). Neuroscience researchers (principal investigators) with a compelling therapeutic rationale and starting materials for a drug development project will be matched with senior-level, industry-seasoned consultants who will design and direct the drug development plan. The principal investigators will conduct the bioactivity assays and biological work, and Contracted Research Organizations (CROs), which will be identified and funded by NIH through separate contracts, will implement all other drug development activities. The principal investigator, consultants, NIH staff, and CRO staff engaged in a project will constitute a Lead Development Team (LDT).